Industry Voices

The dust is starting to settle about what may be long-term in the orthopedic manufacturer-to-hospital supply chain and what may have been an anomaly.

A few months ago, Gary Miller, Ph.D., gave a commencement speech to the University of Florida's graduating engineers. It was a fitting honor for a man who has dedicated decades to the field of engineering and was on the verge of a new chapter himself....

Jean-Paul Burtin was attracted to orthopedics by its possibility for innovation. The enticement did not disappoint.

The oversubscribed $12.5 million Series D round sets Catalyst to expand product lines and build out its infrastructure to support growth.

While autologous live cell therapies are not new, Royal Biologics is creating a unique value proposition through its growing ALC portfolio.

Technology updates, the competitive landscape and surgeon and patient interest are pushing orthopedic companies to speed robotic iterations and innovations.